Business Context and Reporting Period
Precision Optics Corporation, Inc. designs and manufactures optical and illumination systems, primarily medical devices such as endoscopes, endocouplers, and micro-camera assemblies; approximately 6% of its business is military and industrial products. This Form 10-K reports the fiscal year ended June 30, 2016, with comparisons to fiscal 2015—not calendar 2015 Q4.
Financial Results and Liquidity
| Metric | FY 2016 | FY 2015 |
|---|---|---|
| Revenue | $3,916,702 | $3,912,060 |
| Gross profit / margin | $942,021 / 24.1% | $798,271 / 20.4% |
| Operating loss | ($1,055,434) | ($1,213,053) |
| Net loss | ($1,034,765) | ($1,178,793) |
| Net loss per share | ($0.15) | ($0.19) |
| Cash used in operating activities | ($876,298) | ($773,793) |
- Gross margin improved primarily because manufacturing scrap and labor overruns declined. R&D expense was $478,267 versus $492,937; SG&A was $1,551,895 versus $1,545,462.
- At June 30, 2016, cash was $50,059, current assets were $2,022,019, current liabilities were $1,503,961, and working capital was $518,058. Cash was $241,051 and working capital $592,537 a year earlier.
- Debt disclosed was a capital lease with a $39,812 present value ($7,857 current; $31,955 long-term). The filing reports no material off-balance-sheet arrangements.
- Cash declined by $190,992 during the year. Financing provided $661,201 net, including $700,000 gross proceeds from an October 2015 stock placement. Equity issuance increased shares outstanding to 7,539,582 at year-end from 6,389,806.
Material Changes Versus Prior Period
- Revenue was essentially flat, up $4,642. Management said fiberscope and laryngoscope revenue declined, while engineering-service revenue from new customer projects increased; it described the respective changes as amounts representing 25% and 20% of FY 2016 revenue.
- Gross profit rose $143,750 and gross margin increased 3.7 percentage points. Operating and net losses narrowed, but operating cash use increased by $102,505.
- Accounts receivable increased to $750,380 from $588,042, while accounts payable rose to $1,151,561 from $912,150. Customer advances fell from $118,800 to zero.
Outlook, Risks, and Unusual Items
- Going concern: The auditor’s report and management disclosures state that recurring losses and negative operating cash flows raise substantial doubt about the company’s ability to continue as a going concern. Management said available cash might not fund operations through the end of 2016 without additional financing. The auditor gave an unmodified opinion on the financial statements while emphasizing this uncertainty.
- Management is pursuing debt, equity, or a strategic alliance and expects customer development projects may lead to manufacturing orders. It provided no quantified revenue, earnings, or cash-flow guidance. Failure to raise capital or reach positive cash flow could require cost cuts, including reduced R&D, and could disrupt operations.
- Products based on Microprecision optics, micro-camera modules, and 3D endoscopes are central to the growth strategy, but production orders remain limited relative to development work. Commercialization, customer adoption, manufacturing efficiency, and competition remain uncertain.
- Customer concentration is significant: management said seven customers generated approximately 62% of FY 2016 sales; the two largest represented 16% and 12%. Fixed-price purchase orders have represented approximately 25%–50% of revenue in recent years and may not be profitable.
- Other risks include limited cash, dependence on a small number of customers and suppliers, regulatory requirements, product liability, and potential equity dilution. At June 30, 2016, 1,136,000 options and 3,032,794 warrants were outstanding; 823,398 shares remained available under the 2011 plan.
- Management found disclosure controls and internal control over financial reporting ineffective, citing material weaknesses in segregation of accounting duties and inventory valuation. The company also reported related-party rent of $108,000 annually for its main facility.
- FY 2016 included a $32,707 gain from selling previously written-off assets and $22,050 of noncash gains from settling service liabilities with stock. These items affected reported results but were not recurring operating revenue.
Important Facts for Investors to Verify
- Current cash runway, subsequent financing, and whether management’s plans alleviate the going-concern uncertainty.
- Whether engineering projects convert into repeat production revenue and improve cash generation, and whether traditional product sales recover.
- The filing gives inconsistent FY 2016 customer percentages: the MD&A identifies Customer B at 12% and Customer C at 1%, while a financial-statement note reverses those figures. Confirm customer concentration and receivable exposure.
- Progress in remediating the disclosed control weaknesses, particularly accounting-duty segregation and inventory valuation.
- Potential dilution from outstanding options, warrants, plan capacity, and future capital raises; also assess the terms and availability of any new financing.